Lexeo's LX2006 shows sustained neurological benefit in Friedreich ataxia trial through 36 months

PUBT · 1d ago
Lexeo's LX2006 shows sustained neurological benefit in Friedreich ataxia trial through 36 months
  • Lexeo Therapeutics will present new interim Phase 1/2 results for LX2006 in Friedreich ataxia at ICAR, November 10-13, 2026.
  • The gene therapy showed sustained or deepening cardiac and neurological benefits through 36 months of follow-up.
  • Treated participants showed significantly improved neurological outcomes compared with a matched natural history control group.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020700PRIMZONEFULLFEED9867744) on November 02, 2026, and is solely responsible for the information contained therein.